This study is being conducted to evaluate the safety and effectiveness of a new inhaled medication called L606, which contains treprostinil liposome, for people living with Pulmonary Hypertension associated with Interstitial Lung Disease. This condition is a type of high blood pressure in the lungs that occurs in individuals who also have scarring or inflammation of the lung tissue. The treatment is delivered through inhalation, which means the medication is breathed in through the lungs.
Participants in the study will be assigned to receive either L606 or a placebo. This research involves a randomized and double-blind process, meaning that neither the participants nor the researchers know which specific treatment is being administered until the study is finished. The study will monitor how the medication affects the ability to walk and other health factors over a period of time.



Austria
Belgium
Czechia
France
Germany
Italy
Latvia
Poland
Portugal
Spain